Edition:
India

Shilpa Medicare Ltd (SHME.NS)

SHME.NS on National Stock Exchange of India

352.40INR
1:27pm IST
Change (% chg)

Rs-0.65 (-0.18%)
Prev Close
Rs353.05
Open
Rs351.40
Day's High
Rs352.90
Day's Low
Rs349.75
Volume
4,272
Avg. Vol
14,286
52-wk High
Rs548.90
52-wk Low
Rs340.70

Latest Key Developments (Source: Significant Developments)

India's Shilpa Medicare Dec-Qtr Net PAT Falls
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Shilpa Medicare Ltd ::DEC QUARTER CONSOL NET PAT 124.7 MILLION RUPEES VERSUS 173 MILLION RUPEES YEAR AGO.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 1.73 BILLION RUPEES VERSUS 1.86 BILLION RUPEES YEAR AGO.  Full Article

Shilpa Medicare Gets U.S FDA Nod For ANDA Imatinib Mesylate Tablets
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Shilpa Medicare Ltd ::SAYS RECEIVED U.S FOOD AND DRUG ADMINISTRATION APPROVAL FOR ITS ANDA, IMATINIB MESYLATE TABLETS.SAYS DRUG USED IN TREATMENT OF LEUKEMIA AS RECOMMENDED IN LABEL APPROVED BY FDA .  Full Article

Shilpa Medicare Gets USFDA Approval For ANDA Irinotecan HCL Injection USP Single Dose Vials
Tuesday, 1 Jan 2019 

Jan 1 (Reuters) - Shilpa Medicare Ltd ::GETS USFDA APPROVAL FOR ANDA IRINOTECAN HCL INJECTION USP SINGLE DOSE VIALS.  Full Article

India's Shilpa Medicare's Dimethyl Fumarate Capsules Gets Tentative Approval By FDA
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Shilpa Medicare Ltd ::CO'S ANDA FOR DIMETHYL FUMARATE DELAYED RELEASE CAPSULES 120 MG & 240 MG HAS BEEN GRANTED TENTATIVE APPROVAL BY FDA.  Full Article

India's Shilpa Medicare Gets EIR From U.S FDA For Karnataka API Units
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Shilpa Medicare Ltd ::GETS EIR FROM U.S FDA TO API MANUFACTURING FACILITIES AT RAICHUR, KARNATAKA.SAYS INSPECTION WAS CARRIED OUT BETWEEN JANUARY 16 TO JAN 19.  Full Article

India's Shilpa Medicare Says U.S. FDA Issues 3 483 Observations To Co's Karnataka Units
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Shilpa Medicare Ltd ::US FDA COMPLETED INSPECTION OF CO'S API FACILITIES UNIT-I AND UNIT-II LOCATED AT RAICHUR, KARNATAKA.SAYS INSPECTION CLOSED BY US FDA WITH THREE 483 OBSERVATIONS.IN PROCESS OF SUBMISSION OF CAPA PLAN TO REGULATOR WITHIN STIPULATED TIMELINES IN RESPONSE TO FORM 483 ISSUED.  Full Article

Shilpa Medicare Gets 483 Observations From U.S. FDA For SEZ Formulation Facilities In Telangana
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Shilpa Medicare Ltd ::SAYS GOT 483 OBSERVATIONS FROM U.S. FDA IN RELATION TO SEZ FORMULATION FACILITIES SITUATED AT JADCHERLA, TELANGANA.SAYS TOTAL 10 OBSERVATIONS WERE CITED DURING CLOSE UP MEETING.SAYS 7 OBSERVATIONS ARE IMPROVEMENT IN PROCEDURES AND PRACTICES.SAYS 3 OBSERVATIONS RELATED TO SETTING OF ANALYTICAL SPECIFICATIONS, TEST PROCEDURES, METHOD VALIDATION.  Full Article

India's Shilpa Medicare Sept-qtr profit rises
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Shilpa Medicare Ltd ::Sept quarter profit 481.9 million rupees versus 331.9 million rupees year ago.Sept quarter revenue from operations 1.94 billion rupees versus 1.96 billion rupees year ago.  Full Article

India's Shilpa Medicare says Rajendra Dugar resigns as CFO
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Shilpa Medicare Ltd :Says Rajendra Dugar resigns as CFO.  Full Article